Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edoxaban - Daiichi Sankyo Company

Next Previous
X
Search
Drug Profile

Edoxaban - Daiichi Sankyo Company

Alternative Names: DU-176; DU-176b; Edoxaban tosilate hydrate; Edoxaban tosylate; LIXIANA; Lixiana; Lixiana OD; Roteas; SAVAYSA

Latest Information Update: 25 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Kyushu University
  • Class Antithrombotics; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation; Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • Phase III Myocardial infarction; Pulmonary hypertension
  • No development reported Venous thrombosis

Most Recent Events

  • 25 Dec 2023 Updated efficacy data from the phase III ELDERCARE-AF trial in Atrial fibrillation presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
  • 11 Nov 2023 Efficacy data of a phase IIIb ENVISAGE-TAVI AF study in Atrial fibrillation presented at the American Heart Association Scientific Sessions 2023 (AHA-2023)
  • 25 Aug 2023 Updated adverse events data from a phase III ENVISAGE-TAVI AF trial in Atrial fibrillation presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology (ESC-Card-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top